🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

15 results for “LISATA THERAPEUTICS, INC.” Clear

  1. Auto-CD34+ cells

    LISATA THERAPEUTICS, INC.

    Chronic Myocardial Ischemia

    phase 3 mab completed

    1 trial

  2. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

    LISATA THERAPEUTICS, INC.

    Stage IV Melanoma

    phase 3 mab terminated

    1 trial

  3. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial

  4. CLBS12

    LISATA THERAPEUTICS, INC.

    Critical Limb Ischemia

    phase 2 mab completed

    1 trial

  5. CLBS14 (low-dose)

    LISATA THERAPEUTICS, INC.

    Myocardial Ischemia

    phase 2 mab completed

    1 trial

  6. CLBS16

    LISATA THERAPEUTICS, INC.

    Coronary Microvascular Dysfunction

    phase 2 mab terminated

    2 trials

  7. NBS10

    LISATA THERAPEUTICS, INC.

    ST Segment Elevation Myocardial Infarction

    phase 2 mab completed

    1 trial

  8. certepetide

    LISATA THERAPEUTICS, INC.

    Pancreas Cancer

    phase 2 small molecule terminated

    1 trial

  9. certepetide

    LISATA THERAPEUTICS, INC.

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  10. lymphokine-activated killer cells

    LISATA THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 2 mab terminated

    1 trial

  11. therapeutic autologous dendritic cells

    LISATA THERAPEUTICS, INC.

    Melanoma (Skin)

    phase 2 mab completed

    1 trial

  12. Biological/Vaccine: therapeutic autologous dendritic cells.

    LISATA THERAPEUTICS, INC.

    Kidney Cancer

    phase 1 mab terminated

    1 trial

  13. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  14. CLBS119

    LISATA THERAPEUTICS, INC.

    Covid-19

    phase 1 mab terminated

    1 trial

  15. CLBS201

    LISATA THERAPEUTICS, INC.

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources